Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases

British Journal of Surgery

Volumn 101, Issue 5, 2014, Pages 550-557

  Homayounfar, K ^a   Bleckmann, A ^a,b   Helms, H J ^b   Lordick, F ^c   Ruschoff J ^d   Conradi, L C ^a   Sprenger, T ^a   Ghadimi, M ^a   Liersch, T ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL PRACTICE; COLORECTAL TUMOR; COMPARATIVE STUDY; DECISION MAKING; EDUCATION; GENERAL SURGERY; GERMANY; HUMAN; LIVER TUMOR; MEDICAL EDUCATION; METASTASIS; METHODOLOGY; ONCOLOGY; PATIENT CARE; PREOPERATIVE CARE; PUBLIC RELATIONS; QUESTIONNAIRE; STANDARD;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DECISION MAKING; EDUCATION, MEDICAL, GRADUATE; GENERAL SURGERY; GERMANY; HUMANS; INTERPROFESSIONAL RELATIONS; LIVER NEOPLASMS; MEDICAL ONCOLOGY; PATIENT CARE TEAM; PHYSICIAN'S PRACTICE PATTERNS; PREOPERATIVE CARE; QUESTIONNAIRES;

EID: 84896110924     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9436     Document Type: Article

References (34)

1. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825.
2. Kulik U, Bektas H, Klempnauer J, Lehner F,. Repeat liver resection for colorectal metastases. Br J Surg 2013; 100: 926-932.
3. Folprecht G, Grothey A, Alberts S, Raab HR, Köehne CH,. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319.
4. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
5. Folprecht G, Gruenberger T, Bechstein WO, Lordick F, Lang H, Weitz J, et al. Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study. J Clin Oncol 2012; (Suppl 4): Abstract 540.
6. Homayounfar K, Liersch T, Schuetze G, Niessner M, Goralczyk A, Meller J, et al. Two-stage hepatectomy (R0) with portal vein ligation-towards curing patients with extended bilobular colorectal liver metastases. Int J Colorectal Dis 2009; 24: 409-418.
7. Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 2012; 99: 1575-1582.
8. Lamb BW, Sevdalis N, Mostafid H, Vincent C, Green JSA,. Quality improvement in multidisciplinary cancer teams: an investigation of teamwork and clinical decision-making and cross-validation of assessments. Ann Surg Oncol 2011; 18: 3535-3543.
9. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R et al. [Update S3-guideline 'colorectal cancer' 2008.] Z Gastroenterol 2008; 46: 799-840.
10. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Rectal Cancer, Version 3·2012. http://www.nccn.org/professionals/physician-gls/pdf/rectal.pdf [accessed 27 January 2012].
11. NHS Executive,. Manual of Cancer Services Standards. NHS Executive: London, 2004.
12. Hackl C, Gerken M, Loss M, Klinkhammer-Schalke M, Piso P, Schlitt HJ,. A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany. Int J Colorectal Dis 2011; 26: 1475-1481.
13. Cummings LC, Payes JD, Cooper GS,. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007; 109: 718-726.
14. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, et al. [ Gastrointestinal tumors-interdisciplinary discussion over new data.] Onkologie 2011; 34 (Suppl 3): 1-31.
15. Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009; 16: 1844-1851.
16. Adam R, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26: 1635-1641.
17. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939-3945.
18. Bischof DA, Clary BM, Maithel SK, Pawlik TM,. Surgical management of disappearing colorectal liver metastases. Br J Surg 2013; 100: 1414-1420.
19. Tannapfel A, Reinacher-Schick A, Flott-Rahmel B. [Steatohepatitis after chemotherapy for colorectal liver metastases (CASH).] Pathologe 2011; 32: 330-335.
20. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
21. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
22. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982.
23. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911.
24. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al.; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
25. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657.
26. Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502-1509.
27. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7.
28. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D,. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280.
29. Gruttadauria S, Vasta F, Mivervini MI, Piazza T, Arcadipane A, Marcos A, et al. Significance of the effective remnant liver volume in major hepatectomies. Am Surg 2005; 71: 235-240.
30. Homayounfar K, Liersch T, Niessner M, Meller J, Lorf T, Becker H, et al. Multimodal treatment options for bilobar colorectal liver metastases. Langenbecks Arch Surg 2010; 395: 633-641.
31. Ksienski D, Woods R, Speers C, Kennecke H,. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer. Ann Surg Oncol 2010; 17: 3085-3093.
32. Jones RP, Vauthey JN, Adam R, Rees M, Berry D, Jackson R, et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 2012; 99: 1263-1269.
33. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215.
34. Van Cutsem E, Nordlinger B, Cervantes A; ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010; 21 (Suppl 5): v93-v97.